RCM
AXDX

Raging Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Raging Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-24,770
Closed -$6.49M – 40
2017
Q4 		$6.49M Buy
+24,770
New +$5.81M 0.88% 29

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Raging Capital Management's AXDX Position: Q2 2020 in Review

Raging Capital Management sold out of Accelerate Diagnostics (AXDX) in Q2 2020, closing a stake of 10,595 shares — an estimated $883K sold.

Raging Capital Management first reported a position in AXDX in Q1 2015 and held it in 10 quarters. The position peaked at $2.52M in Q4 2018. 123 funds tracked by Wall St. Rank hold AXDX as of Q2 2020.

  • Raging Capital Management reported no remaining Accelerate Diagnostics position as of Q2 2020 after selling out during the quarter.
  • Raging Capital Management sold 10,595 Accelerate Diagnostics shares in Q2 2020, an estimated $883K.
  • Raging Capital Management first reported a position in Accelerate Diagnostics in Q1 2015 and held it in 10 quarters.
  • Raging Capital Management's Accelerate Diagnostics position peaked at $2.52M in Q4 2018.
  • 123 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2020.

Based on Raging Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.